Subject(s)
HLA Antigens/genetics , Microsatellite Repeats , Polymorphism, Genetic , Psoriasis/genetics , Tumor Necrosis Factor-alpha/genetics , Adolescent , Adult , Aged , Aged, 80 and over , Brazil , Case-Control Studies , Disease Progression , Haplotypes , Humans , Middle Aged , Phenotype , Prognosis , Psoriasis/immunology , Psoriasis/pathology , Young AdultSubject(s)
HLA Antigens/genetics , Haplotypes , Psoriasis/genetics , Adolescent , Alleles , Brazil , Child , Female , Humans , MaleSubject(s)
Biomarkers , Histocompatibility Antigens Class I/genetics , Psoriasis/genetics , Psoriasis/immunology , Adolescent , Adult , Child , Chronic Disease , Humans , Middle Aged , Prognosis , Remission, SpontaneousABSTRACT
This study investigated the genetic association of HLA class I genes and TNF-alpha microsatellites. HLA-A, -B, -C typing was carried out in 92 psoriasis vulgaris patients and 160 healthy individuals using a PCR-SSP method. 70 patients and 71 controls were typed for five microsatellite polymorphisms, TNFa-e. HLA-B*13 Cw*06, HLA-B*57 Cw*06 and HLA-B*39 Cw*12 haplotypes were found to be increased in patients with psoriasis type I when compared to controls, which could determine the susceptibility to development of psoriasis. TNFa4, TNFb1, TNFe1 and TNFa2 b1 c2 d4 e1 haplotypes showed a decreased frequency (p < 0.05) in psoriasis patients when compared to controls. HLA-B*13 allele and HLA-B*13 Cw*06, TNFa11 b4 c1 d3 e3 haplotypes showed increased frequencies (p < 0.05) in patients with type II psoriasis, which suggests susceptibility to the onset of psoriasis. Our results detected polymorphisms of the HLA class I and microsatellite TNF locus which could be markers of genetic predisposition to the disease.
Subject(s)
Histocompatibility Antigens Class I/genetics , Psoriasis/genetics , Tumor Necrosis Factor-alpha/genetics , Adolescent , Adult , Aged , Aged, 80 and over , Brazil , Child , Female , Genetic Predisposition to Disease , Humans , Male , Microsatellite Repeats , Middle Aged , Polymerase Chain Reaction , Polymorphism, Genetic , Psoriasis/epidemiology , RiskABSTRACT
The pharmacokinetics of Josamycin was studied in 31 subjects (10 normals, 9 Gilbert's syndrome and 12 compensated liver cirrhosis) after the administration of Josamycin (1 g orally) and in 13 subjects (4 normals, 4 Gilbert's syndrome and 5 compensated liver cirrhosis) after 3-day Josamycin treatment (1 g orally every 12 hours). Josamycin pharmacokinetics was impaired in liver cirrhosis and, to a lesser extent, in Gilbert's syndrome. Moreover, in the three groups of individuals studied the drug accumulated after multiple dosing. These results suggest that a dosage adjustment of Josamycin is recommended when dealing with these patients.
